Last reviewed 2026-04-23 · How we verify

Non-statin LMT

Non-statin LMT (lipid-modifying therapy) reduces low-density lipoprotein cholesterol through a mechanism other than HMG-CoA reductase inhibition.

Non-statin LMT (lipid-modifying therapy) reduces low-density lipoprotein cholesterol through a mechanism other than HMG-CoA reductase inhibition. Used for Dyslipidemia / hypercholesterolemia (specific indication unknown pending phase 3 data).

At a glance

Mechanism of action

Non-statin LMTs represent alternative pathways to lipid lowering, potentially including PCSK9 inhibitors, bempedoic acid, inclisiran, or other novel targets that complement or replace statin therapy. These agents address dyslipidemia through mechanisms such as proprotein convertase subtilisin/kexin type 9 inhibition, xanthine oxidase inhibition, or other lipid metabolism pathways.

Approved indications

• Dyslipidemia / hypercholesterolemia (specific indication unknown pending phase 3 data)

Common side effects

No common side effects on file.

Key clinical trials

• Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia (PHASE3)
• Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin (PHASE3)
• Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II) (PHASE3)
• Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin) (PHASE3)
• Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia) (PHASE4)
• Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan (PHASE3)
• Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN) (PHASE3)
• Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.